Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Down 6.0% in March

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) saw a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 22,100 shares, a decline of 6.0% from the March 15th total of 23,500 shares. Based on an average daily volume of 3,000 shares, the days-to-cover ratio is presently 7.4 days. Approximately 1.2% of the company’s shares are sold short.

Hedge Funds Weigh In On Cyclerion Therapeutics

Several institutional investors have recently modified their holdings of CYCN. Renaissance Technologies LLC grew its stake in shares of Cyclerion Therapeutics by 50.7% in the second quarter. Renaissance Technologies LLC now owns 456,077 shares of the company’s stock worth $250,000 after acquiring an additional 153,519 shares in the last quarter. Tyndall Capital Partners L P acquired a new position in Cyclerion Therapeutics in the third quarter valued at $505,000. Jane Street Group LLC purchased a new stake in shares of Cyclerion Therapeutics in the second quarter valued at about $32,000. Prudential Financial Inc. purchased a new position in Cyclerion Therapeutics during the second quarter worth about $29,000. Finally, Virtu Financial LLC purchased a new position in Cyclerion Therapeutics during the fourth quarter worth about $32,000. Institutional investors and hedge funds own 75.62% of the company’s stock.

Cyclerion Therapeutics Price Performance

Shares of NASDAQ CYCN opened at $3.15 on Wednesday. The business’s 50 day moving average is $3.12 and its two-hundred day moving average is $3.07. Cyclerion Therapeutics has a 52-week low of $1.75 and a 52-week high of $7.00.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults.